v3.26.1
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2024
CNY (¥)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2026
CNY (¥)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
CNY (¥)
Commitments And Contingencies Disclosure [Line Items]            
Accrued contract consideration     $ 1,800,000      
Purchase of property and equipment     440,000   $ 457,000  
Research and development   $ 8,351,000     $ 16,442,000  
SDM Clinical Trial Agreement            
Commitments And Contingencies Disclosure [Line Items]            
Contractual amount     16,700,000     ¥ 114,000,000
Research and development     2,600,000      
Payment for research and development under agreement     4,700,000      
Property and Equipment            
Commitments And Contingencies Disclosure [Line Items]            
Purchase of property and equipment     1,200,000      
Research and development expenses | Gyre Pharmaceuticals            
Commitments And Contingencies Disclosure [Line Items]            
Committed to allocate     $ 44,500,000      
Etorel IP Rights            
Commitments And Contingencies Disclosure [Line Items]            
Contingent royalty minimum payment | ¥ ¥ 35,000,000          
Contingent royalty payment description     For each of the first two years starting from June 2025, the minimum annual commission is RMB 10 million, or approximately $1.5 million, based on the June 30, 2026 spot exchange rate, which has already been included in the IP cost. If the sales-based commission calculated at 5% of annual sales in the first year exceeds RMB 10 million (approximately $1.5 million, based on the June 30, 2026 spot exchange rate) or the commission calculated at 4% of annual sales in the second year exceeds RMB 10 million (approximately $1.5 million, based on the June 30, 2026 spot exchange rate), the excess amount for each year will be recognized as contingent consideration. For the third year through the eighth year, the contingent payments will be calculated at 3%, 2%, 2%, 1%, 1%, and 1% of sales in each year, respectively. For each of the first two years starting from June 2025, the minimum annual commission is RMB 10 million, or approximately $1.5 million, based on the June 30, 2026 spot exchange rate, which has already been included in the IP cost. If the sales-based commission calculated at 5% of annual sales in the first year exceeds RMB 10 million (approximately $1.5 million, based on the June 30, 2026 spot exchange rate) or the commission calculated at 4% of annual sales in the second year exceeds RMB 10 million (approximately $1.5 million, based on the June 30, 2026 spot exchange rate), the excess amount for each year will be recognized as contingent consideration. For the third year through the eighth year, the contingent payments will be calculated at 3%, 2%, 2%, 1%, 1%, and 1% of sales in each year, respectively.    
Contingent royalty payment sales for first year | ¥       ¥ 10,000,000    
Contingent royalty payment sales for second year | ¥       ¥ 10,000,000    
Contingent royalty payment sales spot exchange rate for first year     $ 1,500,000      
Contingent royalty payment sales spot exchange rate for second year     $ 1,500,000      
Contingent royalty payment percentage of sale for first year     5.00%     5.00%
Contingent royalty payment percentage of sale for second year     4.00%     4.00%
Contingent royalty payment percentage of sale for third year     3.00%     3.00%
Contingent royalty payment percentage of sale for fourth year     2.00%     2.00%
Contingent royalty payment percentage of sale for fifth year     2.00%     2.00%
Contingent royalty payment percentage of sale for sixth year     1.00%     1.00%
Contingent royalty payment percentage of sale for seventh year     1.00%     1.00%
Contingent royalty payment percentage of sale for eighth year     1.00%     1.00%
Minimum payments based on spot exchange rate     $ 5,100,000      
Annual sales commission for second year exceeding amount | ¥           ¥ 10
Annual sales commission spot exchange rate for second year exceeding amount     1,500,000      
Hydronidone            
Commitments And Contingencies Disclosure [Line Items]            
Payments for exchange of intellectual property rights     $ 0      
Contingent royalty payment percentage of sale for first year     10.00%     10.00%
Contingent royalty payment percentage of sale for second year     14.00%     14.00%
Contingent royalty payment percentage of sale for third year     16.00%     16.00%
Contingent royalty payment percentage of sale for fourth year     16.00%     16.00%
Contingent royalty payment percentage of sale for fifth year     16.00%     16.00%
Contingent royalty payment percentage of sale for sixth year     16.00%     16.00%
Contingent royalty payment percentage of sale for seventh year     16.00%     16.00%
Contingent royalty payment percentage of sale for eighth year     15.00%     15.00%
Contingent royalty payments percentage of sale for ninth year     14.00%     14.00%
Contingent royalty payments percentage of sale for tenth year     12.00%     12.00%
Contingent royalty payments percentage of sale for eleventh year     10.00%     10.00%
Contingent royalty payment percentage of sale for twelfth year     8.00%     8.00%
Hydronidone | GNI            
Commitments And Contingencies Disclosure [Line Items]            
Committed to allocate     $ 8,500,000      
Hydronidone | Gyre Pharmaceuticals | NDA Passes the NMPA's Review and Inspection            
Commitments And Contingencies Disclosure [Line Items]            
Obligation to pay in exchange for the intellectual property rights     1,200,000     ¥ 8,300,000
Hydronidone | Gyre Pharmaceuticals | NMPA's Approval of the NDA            
Commitments And Contingencies Disclosure [Line Items]            
Obligation to pay in exchange for the intellectual property rights     $ 7,300,000     ¥ 49,600,000